Involved in many disease pathologies, DUBs are attractive therapeutic targets


World-leading DUB platform translating scientific advances into transformative therapies


First-in-class small molecule DUB inhibitors developed in-house and with partners


Multiple in-house DUB inhibitor programs in the clinic or approaching clinical development

Mission Therapeutics

Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases including Parkinson’s Disease (PD) and other neuro-degenerative conditions, heart and kidney diseases, fibrosis, and rare mitochondria diseases, by developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs).

Our lead candidates – MTX325 and MTX652 – aim to inhibit USP30, a DUB which can retard the essential cellular quality control process called mitophagy.

To hear our CEO discuss our technology, programs, recent progress and strategy, watch our Corporate Presentation.



£117 million

Capital Investment


DUB targets explored


In the DUB field

Commercializing expert research into

Dubs and Ubiquitin pathway

Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.

Mission Therapeutics © website by Instinctif Partners